Arsenic trioxide (ATO) alone and/or combination with all trans retinoic acid (ATRA) have been used successfully for the cure of APL patients who have PML–RARα oncogene, providing a complete treatment and maximizing the survival rate of patients.2, 4, 5. This evidence concerns the gene RARA and acute promyelocytic leukemia.